SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (2753)5/14/1999 2:37:00 PM
From: LLCF  Read Replies (2) | Respond to of 10280
 
Repeat... anyone know who was funding this thing? It looks to me like no change except J&J won't co-promote but will take royalies instead for strategic (sales) reasons... looks like market has totally mis-read this?

dAK



To: Biomaven who wrote (2753)5/14/1999 2:57:00 PM
From: quidditch  Respond to of 10280
 
Some time ago I had PM'd to Mazen regarding J&J's pattern of conduct leading smaller venture partners down a joint funding path and then pulling out at nearly last minute as some "change in strategic focus" mandated a decision not to continue. While this is another punch in gut during this difficult period, I can't say that I'm surprised.

Regards. Steven



To: Biomaven who wrote (2753)5/14/1999 2:58:00 PM
From: Art Vandelay AIA  Respond to of 10280
 
To clarify, SEPR was paying for the development, but was to be at least partially reimbursed by J&J when the drug was approved and taken to market.